Trial · NCT02152761
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Bimagrumab 700 mg | week 12 | 1.066 | Standard Error 0.0107 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Bimagrumab 210 mg | week 12 | 1.052 | Standard Error 0.0109 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Active Total Efficacy (AT:E) | week 12 | 1.059 | Standard Error 0.0096 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Placebo | week 12 | 1.009 | Standard Error 0.0103 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Bimagrumab 700 mg | week 24 | 1.064 | Standard Error 0.0113 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Bimagrumab 210 mg | week 24 | 1.042 | Standard Error 0.0115 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Active Total Efficacy (AT:E) | week 24 | 1.053 | Standard Error 0.0101 | kg |
| Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 | Placebo | week 24 | 0.996 | Standard Error 0.0109 | kg |
| Change From Baseline in Gait Speed at Week 24 (Meters/Sec) | Bimagrumab 700 mg | 0.268 | Standard Error 0.0599 | meters per second | |
| Change From Baseline in Gait Speed at Week 24 (Meters/Sec) | Bimagrumab 210 mg | 0.350 | Standard Error 0.0617 | meters per second | |
| Change From Baseline in Gait Speed at Week 24 (Meters/Sec) | Placebo | 0.339 | Standard Error 0.0607 | meters per second | |
| Change From Baseline in Short Physical Performance Battery at Weeks 24 | Bimagrumab 700 mg | 2.331 | Standard Error 0.5436 | scores on a scale | |
| Change From Baseline in Short Physical Performance Battery at Weeks 24 | Bimagrumab 210 mg | 3.535 | Standard Error 0.5623 | scores on a scale | |
| Change From Baseline in Short Physical Performance Battery at Weeks 24 | Placebo | 2.702 | Standard Error 0.5516 | scores on a scale | |
| Incidence of Falls up to Week 48 | Bimagrumab 700 mg | 0.31 | 95% Confidence Interval 0.14 to 0.70 | Number of Falls per week | |
| Incidence of Falls up to Week 48 | Bimagrumab 210 mg | 0.45 | 95% Confidence Interval 0.20 to 0.99 | Number of Falls per week | |
| Incidence of Falls up to Week 48 | Bimagrumab 70mg | 0.36 | 95% Confidence Interval 0.13 to 0.97 | Number of Falls per week | |
| Incidence of Falls up to Week 48 | Placebo | 0.29 | 95% Confidence Interval 0.13 to 0.64 | Number of Falls per week |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02152761/results